奥克雷利祖马布诱导的中性质减退:严重程度,复发和管理. 一个法国国家药监测研究
Vincent Brochard1, Benjamin Le Vavasseur2, Sylvine Pinel3
1Department of Neurology, Hôpital Fondation Adolphe de Rothschild, Paris, France.
Multiple sclerosis and related disorders
|September 27, 2025
概括
奥克雷利祖马布诱导的中性衰竭 (OIN) 通常无症状,通常不严重,尽管它可能会复发. 在重新引入ocrelizumab之前,建议仔细考虑患者因素和替代方案.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥克雷利祖马布是治疗多发性硬化症 (MS) 的有效抗CD20疗法.
- 抗CD20治疗中,中性是已知的风险之一.
- 关于ocrelizumab诱导的中性质减退症 (OIN) 严重程度,复发和管理的数据有限.
研究的目的:
- 描述OIN的临床表现,复发风险和管理策略.
- 分析在法国药监数据库中报告的OIN病例.
主要方法:
- 对OIN报告的回顾性观察性研究.
- 通过临床医生问卷收集的数据.
- 包括中度至重度中性质衰竭 (<1.0 G/L) 的患者.
主要成果:
- 分析了34例OIN病例;大多数是晚发 (>周期后4周).
- 大多数患者 (55.9%) 无症状;32.4% 感染.
- 在15名患者中重新引入ocrelizumab导致4名患者复发 (26.6%).
结论:
- OIN通常是间歇性的,偶然发现的,并且通常不严重.
- 一个显著的复发率 (大约. 25%) 存在于ocrelizumab重试后.
- 用ocrelizumab重新挑战需要仔细评估MS状态和治疗替代方案.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
588
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
588
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
602
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
602
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
